A general route to unsubstituted N-aryl and heteroarylaminobenzenesulfonamides
摘要:
Starting from suitably protected 3- and 4-aminobenzenesulfonamides, a practical two-step strategy for the synthesis of unsubstituted N-aryl and heteroarylaminobenzenesulfonamides was devised. Strong bases are tolerated during the N-arylation step. Overall moderate to excellent yields are reported. (C) 2011 Elsevier Ltd. All rights reserved.
[EN] 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY [FR] HÉTÉROARYLAMINOSULFONAMIDES À 5 CHAÎNONS POUR LE TRAITEMENT D'ÉTATS À MÉDIATION PAR UNE ACTIVITÉ CFTR DÉFICIENTE
[EN] 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY<br/>[FR] HÉTÉROARYLAMINOSULFONAMIDES À 5 CHAÎNONS POUR LE TRAITEMENT D'ÉTATS À MÉDIATION PAR UNE ACTIVITÉ CFTR DÉFICIENTE
申请人:GENZYME CORP
公开号:WO2021097057A1
公开(公告)日:2021-05-20
The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.
Starting from suitably protected 3- and 4-aminobenzenesulfonamides, a practical two-step strategy for the synthesis of unsubstituted N-aryl and heteroarylaminobenzenesulfonamides was devised. Strong bases are tolerated during the N-arylation step. Overall moderate to excellent yields are reported. (C) 2011 Elsevier Ltd. All rights reserved.